ADVANCES IN SURGICAL RESECTION TECHNIQUES FOR GLIOBLASTOMA: IMPLICATIONS FOR SURVIVAL AND PRECISION. A REVIEW OF CURRENT LITERATURE
Abstract
Introduction: Glioblastoma multiforme is the most common and aggressive type of primary brain tumor, often presenting with a poor prognosis and limited survival, despite available treatment options. The tumor’s inherent resistance to treatment and its heterogeneity pose significant challenges for management.
Aim: This article aims to assess the impact of various surgical resection techniques on the survival of patients with glioblastoma, focusing on the importance of maximizing tumor resection while minimizing postoperative complications.
Methods and Materials: A literature review was conducted, focusing on studies published in the past five years. The review examined factors such as the extent of surgical resection, the use of intraoperative guidance, and postoperative care, evaluating their influence on survival rates.
Discussion: Complete tumor resection is positively associated with improved survival, but the extent of resection remains a debated topic. Advanced surgical methods, including fluorescence-guided imaging, are increasingly used to improve resection accuracy and reduce harm to healthy tissue. However, the prognosis for glioblastoma patients remains poor, and new approaches are needed to address the tumor’s resistance mechanisms.
Conclusions: Surgical resection is a key component of glioblastoma treatment, with a significant impact on survival. However, there is a need for further clinical studies to refine surgical methods, optimize resection strategies, and develop new therapeutic options to improve long-term survival for patients.
References
Alifieris, C., & Trafalis, D. T. (2020). Glioblastoma multiforme: Pathogenesis and treatment. Pharmacology & Therapeutics, 25, 111810. https://doi.org/10.1016/j.biopha.2021.111810
Andrades, J., Daniels, J., & Hampson, R. (2022). The role of extent of surgical resection in glioblastoma management. Cureus, 14(6), e11897. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269017/
Gempt, J., Foerschler, A., Buchmann, N., Picht, T., Schramm, J., Meyer, B., et al. (2021). Surgical decision-making in gliomas: The WHO and ASA scores are reliable predictors of outcome. Acta Neurochirurgica, 163(5), 1247–1255. https://doi.org/10.1007/s00701-021-04776-5
Glioblastoma Foundation. (n.d.). Glioblastoma multiforme. https://glioblastomafoundation.org/news/glioblastoma-multiforme (Accessed May 2, 2025)
Kim, J. W., Lee, Y. S., & Lee, S. H. (2020). Neurological outcomes following glioblastoma surgery: A review of postoperative complications and management. Neurosurgery, 87(3), 657–664. https://doi.org/10.1007/s11060-020-03556-y
Khan, A., Daoud, H., Nguyen, A., & Haji, F. A. (2023). Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment. Cureus, 15(6), e81872. https://doi.org/10.7759/cureus.81872
Li, Y. M., Zhang, Z. H., Luo, Z., Zheng, Y., & Wang, Y. (2022). Fluorescence-guided resection of glioblastoma multiforme: Recent advances and perspectives. Frontiers in Oncology, 12, 914302. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143023/
Menck, N., Bian, J., Wong, F., et al. (2023). Glioblastoma recurrence and prognosis: A review of treatment options and factors affecting survival. Journal of Clinical Oncology, 40(18), 1749–1759. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12060197/
Schenker, M., Martin, J., Diaz, J., et al. (2021). Clinical and molecular biomarkers in glioblastoma multiforme: Implications for treatment. Annals of Oncology, 34(5), 687–697. https://doi.org/10.1007/s11060-020-03556-y
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2024). Cancer statistics, 2024. CA: A Cancer Journal for Clinicians, 74(2), 102–125. https://doi.org/10.3322/caac.21613
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J. B., Janzer, R. C., et al. (2005). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma. The New England Journal of Medicine, 352(10), 987–996. https://doi.org/10.3322/caac.21613
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J. B., Janzer, R. C., et al. (2005). Radiotherapy and temozolomide for newly diagnosed glioblastoma. The New England Journal of Medicine, 352(10), 987–996. https://doi.org/10.1007/s11060-020-03556-y
Stupp, R., Weller, M., Aldape, K., et al. (2024). RANO classification of extent of resection in glioblastoma: Proposal and validation. The Lancet Oncology. https://doi.org/10.1016/S1470-2045(24)00130-X
Tzortzaki, E. G., Pavlakis, E., Lykoudis, P., et al. (2022). Surgical resection and its impact on glioblastoma survival. Journal of Neuro-Oncology, 129(2), 215–224. https://doi.org/10.3322/caac.21613
Weller, M., van den Bent, M., Tonn, J. C., et al. (2021). Lifting the clinical trial burden in glioblastoma. Neuro-Oncology, 23(1), 1–13. https://doi.org/10.1007/s12036-020-02202-x
Zeng, L., Yang, H., Li, H., Chen, R., Chen, J., & Yu, J. (2024). Risk factors for and molecular pathology characteristics of systemic metastasis of adult cerebral glioblastoma: A pooled individual patient data analysis and systematic review. Journal of Neurological Surgery Part A: Central European Neurosurgery. https://doi.org/10.1055/a-2479-9978
Views:
0
Downloads:
0
Copyright (c) 2025 Wiktoria Suchcicka, Aleksandra Borowy, Aleksandra Chajnowska, Julia Guzowska, Patrycja Rzeźnik, Maciej Sobczyk, Weronika Stachera, Julia Stępień, Barbara Wołoszyn, Małgorzata Zach
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
